Tumor-derived TGF-β inhibits mitochondrial respiration to suppress IFN-γ production by human CD4


Journal

Science signaling
ISSN: 1937-9145
Titre abrégé: Sci Signal
Pays: United States
ID NLM: 101465400

Informations de publication

Date de publication:
17 09 2019
Historique:
entrez: 19 9 2019
pubmed: 19 9 2019
medline: 11 8 2020
Statut: epublish

Résumé

Transforming growth factor-β (TGF-β) is produced by tumors, and increased amounts of this cytokine in the tumor microenvironment and serum are associated with poor patient survival. TGF-β-mediated suppression of antitumor T cell responses contributes to tumor growth and survival. However, TGF-β also has tumor-suppressive activity; thus, dissecting cell type-specific molecular effects may inform therapeutic strategies targeting this cytokine. Here, using human peripheral and tumor-associated lymphocytes, we investigated how tumor-derived TGF-β suppresses a key antitumor function of CD4

Identifiants

pubmed: 31530731
pii: 12/599/eaav3334
doi: 10.1126/scisignal.aav3334
pii:
doi:

Substances chimiques

Smad Proteins 0
Transforming Growth Factor beta 0
Interferon-gamma 82115-62-6
Adenosine Triphosphate 8L70Q75FXE
Mitochondrial Proton-Translocating ATPases EC 3.6.3.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Sarah Dimeloe (S)

Immunobiology Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland. s.k.dimeloe@bham.ac.uk chess@uhbs.ch ch818@cam.ac.uk.
Institute of Immunology and Immunotherapy and Institute of Metabolism and Systems Research, University of Birmingham, Birmingham B15 2TT, UK.

Patrick Gubser (P)

Immunobiology Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.

Jordan Loeliger (J)

Immunobiology Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.

Corina Frick (C)

Immunobiology Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.

Leyla Develioglu (L)

Immunobiology Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.

Marco Fischer (M)

Immunobiology Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.

Florian Marquardsen (F)

Immunodeficiency Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.

Glenn R Bantug (GR)

Immunobiology Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.

Daniela Thommen (D)

Cancer Immunology Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.

Yannic Lecoultre (Y)

Immunobiology Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.

Alfred Zippelius (A)

Cancer Immunology Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland.

Anja Langenkamp (A)

Roche Innovation Center Basel, 4070 Basel, Switzerland.

Christoph Hess (C)

Immunobiology Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland. s.k.dimeloe@bham.ac.uk chess@uhbs.ch ch818@cam.ac.uk.
Department of Medicine, University of Cambridge, Cambridge CB2 0AW, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH